10th Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 22-23, 2015 

 
 

A mutli-disciplinary gathering where you can gain new insights and refresh on new ideas
through networking and presentations

Djamal B., Arisan Therapeutics

Fragment-based approaches to find new small molecule drug candidates are now part of most drug discovery campaigns. This was not the case less than a decade ago. However with at least one drug on the market and more than twenty in clinical development whose origins can be traced to fragment-based screens, understanding the role and limitations of fragment-based drug design in order to capitalize on its promise and make it an efficient and seamless part of drug discovery is becoming more important than ever.

The challenge of fragment-based drug design campaigns has always been progressing fragment hits against the target compound to obtaining a clinical candidate. Via case studies on success stories and compounds moving forward or not in preclinical development, join fellow biophysical and medicinal chemists at Cambridge Healthtech Institute's Fragment-Based Drug Discovery to learn about best practices and pitfalls to avoid. This day-and-a-half meeting is in the second half of CHI’s larger Drug Discovery Chemistry event.

Preliminary Agenda


NEW CHEMISTRY/NEW TARGETS

Irreversible Tethering: Fragment-Based Drug Discovery Technology for Covalent Enzyme and PPI Inhibitor Discovery

Alexander Statsyuk, Ph.D., Assistant Professor, Chemistry Department, Northwestern University

Fragment Hopping to Design Selective Inhibitors for Beta-catenin/T Cell Factor Interactions

Haitao (Mark) Ji, Ph.D., Assistant Professor, Chemistry, University of Utah

Using Fragment-Based Lead Discovery towards Alternate Mechanisms: Inhibiting Ubiquitin Binding to USP7

Till Maurer, Ph.D., Senior Scientist, Structural Biology, Genentech

Identification of Fragment Hits that Bind the SAM Pocket of COMT

Mark Hixon, Ph.D., Principal Scientist, Medicinal Chemistry, Takeda


FRAGMENTS FOR CANCER

Attacking Cancer with Fragments: BCL2 Case Studies

Andrew Petros, Ph.D., Associate Research Fellow, Research & Development, AbbVie

Tankyrase Inhibitors

Rod Hubbard, Ph.D., Senior Fellow, Structural Sciences, Vernalis


DEBATES, ADVANCES AND CASE STUDIES IN FRAGMENT-BASED DISCOVERY

Experiences with Fragment Libraries at Astex

Alison Woolford, Ph.D., Associate Director, Chemistry, Astex Pharmaceuticals

Ligand Deconstruction and Library Design: Why Some Fragment Positions are Conserved and Others are Not

Sandor Vajda, Ph.D., Professor, Biomedical Engineering and Chemistry, Boston University

Exploring Possible Drug Target Conformational Changes by Fragment Screening

Barry Finzel, Ph.D., Professor, Medicinal Chemistry, University of Minnesota

Fragment-to-Lead Case Study: Optimization of a Non-Kinase Target

Chris McBride, Ph.D., Senior Scientist, Medicinal Chemistry, Takeda



For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com